http://localhost:8080/xmlui/handle/123456789/8229 45 - 128 2026-04-08T23:00:34Z http://localhost:8080/xmlui/handle/123456789/8245 Title: The changes of oxidative stress markers and Vitamin E in patients with diabetes using SGLT2 inhibitors Authors: Padalkar, Pradnya 2024-01-01T00:00:00Z http://localhost:8080/xmlui/handle/123456789/8242 Title: Fibroblast growth factors: properties, biosynthesis, biological functions, therapeutic applications and engineering Authors: Tiwari, Nitin; Tiwari, Ashok; Mehra, Lalita; dkk. Abstract: Fibroblast Growth Factors (FGFs) function as signaling molecules within various signaling pathways, regulating the proliferation, migration, and differentiation of soft connective tissues, nerves, epithelial tissue, and bone. The FGF family comprises 22 members, with acidic Fibroblast Growth Factor (aFGF/FGF-1) and basic Fibroblast Growth Factor (bFGF/ FGF-2) being of primary significance. This article explores the biochemical and biological properties of different FGFs, elucidating their roles in various biological processes. Additionally, it delves into the interactions between FGFs and Receptor tyrosine kinases (RTKs), which activate several cell signaling cascades, such as the RAS/MAPK (Mitogen-activated Protein Kinase) pathway, PI3K (phosphoinositide 3-kinase)/AKT (v-akt murine thymoma viral oncogene homolog) pathway, PLC-γ (Phospholipase C-γ) pathway, and Signal Transducer and Activator of Transcription (STAT) pathway, to facilitate diverse cellular functions. The article also examines methods for engineering FGFs, including N-terminal truncation, point mutations, or combinations thereof, for therapeutic applications in tissue regeneration, angiogenesis, and repairing damaged tissues such as cartilage, bone, ligaments, and skin. Finally, it concludes with a discussion of the delivery systems for FGFs, encompassing scaffolds, hydrogels, as well as nano- and micro-particulate methods. 2024-01-01T00:00:00Z http://localhost:8080/xmlui/handle/123456789/8240 Title: Unveiling the latest insights into Androgen Receptors in Prostate Cancer Authors: Zakari, Suleiman; Ekenwaneze, Christogonus Chichebe; Amadi, Emmanuel Chimuebuka; dkk. Abstract: Prostate cancer (PCa) is a major cause of cancer-related mortality worldwide, with a rising incidence observed over the years. The androgen receptor (AR) signaling pathway plays a pivotal role in male development and maintaining masculine characteristics. Dysregulation of AR signaling in PCa can lead to disease progression and resistance to standard therapies. Understanding the intricate regulation and function of AR in both healthy and diseased states is crucial for developing effective treatment strategies. This review comprehensively explores the role of androgen receptors in PCa susceptibility, disease progression, and treatment response by analyzing recent literature. An extensive search of peer-reviewed publications in major databases, including PubMed, Scopus, and Web of Science, was conducted using specific keywords related to androgen receptor, prostate cancer, disease progression, and treatment resistance. Relevant conference abstracts and clinical trial reports were also included. The review presents an overview of the role of androgen receptors in PCa initiation, progression, and treatment resistance. It also highlights the role of SPOP as an emerging biomarker associated with AR signaling dysregulation and their potential utility for early detection and personalized treatment approaches. Additionally, recent advances in targeting the AR pathway for novel therapeutic strategies to improve patient outcomes and overcome treatment resistance in advanced PCa are discussed. The findings contribute to a comprehensive understanding of the AR signaling pathway in PCa and offer insights into its multifaceted role in disease development and treatment response. They may pave the way for innovative therapeutic interventions and precision medicine approaches based on specific AR signaling profiles, enhancing patient care and reducing the burden of this lethal disease. 2024-01-01T00:00:00Z http://localhost:8080/xmlui/handle/123456789/8239 Title: Creatinine normalization approach to diluted urine samples screened by LC-MS/MS method Authors: Karakukcu, Cigdem; Kocer, Derya; Uzen, Veysel; Saracoglu, Hatice Abstract: Objectives: Urine is the most used matrix in drug analysis; however, it is susceptible to adulteration or tampering. Urine creatinine is the most important urine integrity parameter used as an indicator of dilution. This study aimed to evaluate the prevalence of diluted urine samples and the change in positivity after creatinine normalization. Methods: Urine samples screened by the LC-MS/MS method over a 3.5-year period (n=21,927) were included in the study. Positivity rates were evaluated in both total and diluted urine samples. Additionally, the impact of creatinine normalization on samples with substance concentrations above the limit of quantitation (LOQ) and below the cut-off was investigated. Results: A total of 350,832 tests were conducted on 21,927 urine samples, resulting in an overall positivity rate of 21.2% (n=4652). The ratio of diluted urine was 1.6% (n=343), with 61.5% (n=211) testing negative (<LOQ), 23.3% (n=80) testing positive (at least one substance >cut-off), and 15.2% (n=52) testing above LOQ and below cut-off. After creatinine normalization in diluted urines, the sample positivity rate increased from 23.3% (n=80) to 33.8% (n=116) (p<0.001), and the substance positivity rate increased from 2.3% (n=125) to 3.9% (n=212) (p<0.001). Conclusion: Precautions should be taken in reporting diluted urine samples to avoid reporting false negative results. The creatinine normalization approach shows promise in laboratories using quantitative screening methods such as LC-MS/MS for samples with substance concentrations above the LOQ and below the cut-off. However, more clinical and laboratory collaboration is needed for its routine application. 2024-01-01T00:00:00Z